Ovarian Cancer Coverage from Every Angle
ABOUT
SECTIONS
JNCCN Spotlights
Videos
News
Medical Literature
CE Activities
Clinical Trials
For Your Patients
NCCN RESOURCES
NCCN Guidelines
®
NCCN Compendium
®
NCCN Templates
®
NCCN Guidelines for Patients®
360 HUB
Advanced Skin Cancers
CLL/MCL
Multiple Myeloma
Non–Small Cell Lung Cancer
Ovarian Cancer
JNCCN
Editor:
Joyce F. Liu, MD, MPH
Advertisement
Advertisement
News
BRCA
Status May Help Guide Platinum Rechallenge in Ovarian Cancer
ASCO 2026: Chemotherapy-Free Combination for Heavily Pretreated Platinum-Resistant Ovarian Cancer
ASCO 2026: Short-Term Fasting During Neoadjuvant Chemotherapy May Improve Outcomes in Advanced Ovarian Cancer
ASCO 2026: Chiauranib Plus Paclitaxel Improves Progression-Free Survival in Platinum-Resistant Ovarian Cancer
Determining Standard of Care First-Line Treatment in Advanced, Low-Grade Serous Ovarian Carcinoma
Final Overall Survival Results From ROSELLA in Platinum-Resistant Ovarian Cancer
FDA Approves Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer
JNCCN Spotlights
?
Olaparib
Bevacizumab
(UPDATE) Niraparib
Mirvetuximab Soravtasine-gynx (Elahere)
Trametinib
View More >
Advertisement
Resources
For your Patients
Copyright ©
2026
National Comprehensive Cancer Network, All Rights Reserved
Bots not welcome here
